指南与共识湿疹皮炎与荨麻疹

国际共识:特应性皮炎甲氨蝶呤给药方案eDelphi研究

International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2024-08-01

本研究通过三回合电子德尔菲(eDelphi)调查,旨在就成人和儿童特应性皮炎(AD)的甲氨蝶呤(MTX)给药方案达成国际共识。共有152名参与者完成第一轮,最终19项提案全部达成共识,涵盖试验剂量、起始剂量、最大剂量、给药途径、给药方案、停药管理、治疗疗程和叶酸补充等主题。

要点

  • 共19项关于MTX给药方案的提案达成国际共识。
  • 共识涵盖试验剂量、起始剂量、最大剂量及给药途径等。
  • 共识旨在指导处方决策并促进全球AD治疗标准化。

核心结论

  • 本eDelphi研究就成人和儿童AD的MTX给药方案达成19项提案的共识。
  • 共识结果旨在指导处方决策并鼓励全球AD中MTX使用的标准化方法。

研究设计与样本

  • 研究为电子德尔菲(eDelphi)研究,于2021年10月至2022年9月进行。
  • 通过皮肤病学会和AD兴趣小组招募,参与者为有MTX治疗AD经验的皮肤科医生和住院医师。
  • 研究包括三轮在线调查,第一轮基于系统文献综述,后续轮次根据前一轮结果调整。
  • 参与者对19项提案采用9分制评分(1-3不同意,4-6既不同意也不同意,7-9同意)。
  • 共识定义为至少70%参与者同意且少于15%不同意;前三轮未达成共识的提案在共识会议上讨论,共识定义为不同意少于30%。

主要发现

  • 第一轮有152名参与者完成,104名(68%)完成所有调查轮次,43名(28%)参加共识会议。
  • 第一轮达成7项提案共识,第二轮达成4项,第三轮达成6项。
  • 最后2项提案在共识会议期间达成共识。

关键数值与推荐

  • 共识主题包括试验剂量、起始剂量、最大剂量、给药途径、给药方案、停药管理、治疗疗程和叶酸补充。
  • 具体剂量数值未在摘要中报告。

临床怎么用

  • 共识结果可用于指导成人和儿童AD患者MTX的处方决策。
  • 建议采用标准化的全球方法使用MTX治疗AD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies. OBJECTIVE: The aim of this study was to achieve international consensus among AD experts to standardize the dosing regimen for MTX treatment in adults and children with AD. METHODS: An electronic Delphi (eDelphi) study was conducted from October 2021 to September 2022. Recruitment was conducted through dermatology societies and AD interest groups. Participation was open to dermatologists and dermatology residents experienced in treating AD patients with MTX. The study consisted of three online rounds. The first round was informed by a systematic review of relevant literature, and subsequent rounds were adjusted based on the results of the previous round. Participants voted on 19 proposals using a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree). Consensus was achieved when at least 70% of participants agreed, and less than 15% disagreed. Proposals that did not reach consensus in the first three rounds were discussed in a consensus meeting, where consensus was defined as less than 30% disagreement. RESULTS: In total, 152 participants completed Round 1, 104 (68%) completed all survey rounds, and 43 (28%) joined the consensus meeting. Consensus was achieved on 7 proposals in Round 1, 4 in Round 2 and 6 in Round 3. The final 2 proposals reached consensus during the consensus meeting. Consensus topics include test dose, start dose, maximum dose, administration route, dosing schedule, management of stopping treatment, treatment duration and folic acid supplementation. CONCLUSIONS: This eDelphi study achieved consensus on 19 proposals related to MTX dosing for adults and children with AD. These results aim to guide prescribing decisions and encourage a standardized global approach to MTX use in AD.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Caron AGM, van Huizen AM, Musters AAH, et al. International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study. J Eur Acad Dermatol Venereol. 2024. PMID: 39087636. doi:10.1111/jdv.20271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。